FEB-28-08: A statement issued by Bayer AG this week, they allege that two recent studies regarding their drug Trasylol are flawed. But a consumer advocacy group called Public Citizen's Health Research Group, has made statements that they believe the studies conducted on the drug are convincing enough that the drug is a danger to those who receive it. [MORE: TRASYLOL STUDY FLAWED]

---

FEB-25-08: If the February 17th edition of 60 Minutes on CBS wasn't enough to condemn Trasylol in the eyes of Americans, the publication of two additional studies slamming the safety of Trasylol should convince any remaining doubters regarding the mounting evidence that Trasylol leads to an increase in death and kidney failure. [MORE: MEDIA BASHES TRASYLOL]

---

FEB-18-08: There are several lawsuits that are being launched. Some are adding up into tens of millions of dollars. This is both for alleged negligence on the part of Bayer AG. Other lawsuits are focusing on the loss of lives due to the use of Trasylol. [MORE: BUILDING TRASYLOL LAWSUITS]

---

FEB-16-08: Managno was involved in a study of Trasylol, involving 5,065 patients in 17 countries. His study found a link between kidney failure requiring dialysis and increased death in patients given Trasylol. That study was published in January 2006 and in September 2006, was presented to the FDA at a meeting. [MORE: TOO MANY TRASYLOL DEATHS]

---

FEB-16-08: Lawsuits have been filed against Bayer AG on behalf of plaintiffs located all over the United States due to alleged suffering of kidney damage as a result of being prescribed Trasylol, which is a drug used during coronary artery bypass graft surgery to prevent excessive bleeding. [MORE: TRASYLOL ON 60 MINUTES]

---

NOV-19-07: By the time Bayer AG caved to pressure from regulators and pulled Trasylol from the global marketplace earlier this month, an estimated 4.8 million cardiac patients had received the suspended drug since it was first introduced in 1993. Many of those patients, having experienced kidney failure, stroke or heart problems since receiving Trasylol, known generically as aprotinin, may be unaware that it was the Trasylol that lay at the root of their troubles. [MORE: TRASYLOL WAIT]

---

NOV-13-07: Two days after announcing that Trasylol was subject to a global recall over concern for continued risk of heart attack, kidney failure and death, Bayer AG quietly posted the final report on the study that got them into so much hot water 18 months ago. [MORE: TRASYLOL KILLS]

---

NOV-10-07: In the days immediately following the widespread voluntary recall of Trasylol from the world pharmaceutical market, it has become increasingly clear that Bayer AG has taken this action as a precaution, and has no plans to abandon Trasylol entirely save for the potential of damming results from a randomized Canadian study. [MORE: DEATHWATCH CONTINUES]

---

NOV-05-07: Long under a cloud of suspicion and concern, the reputation of Trasylol was further sullied a few weeks ago when the Ottawa-based clinical trial was abruptly halted after it was found that Trasylol could be linked to a higher risk of death than other drugs. [MORE: TRASYLOL SALES HALTED]

---

JUL-15-07: The first lawsuits against Bayer, maker of Trasylol, were filed earlier this year. On January 25, 2007 a lawsuit was filed on behalf of Ada Williams who was given Trasylol and suffered kidney failure. She now requires kidney dialysis three times a week. The lawsuit seeks damages for pain and suffering and medical costs. [MORE: TRASYLOL LAWSUITS FILED]

---

FEB-17-08: Trasylol (aprotinin) was FDA approved for sale in the US in 1993, as an anti-clotting medication for limited use with patients who at a high risk of blood loss while undergoing coronary artery bypass surgery. [MORE: TRASYLOL DEATH RATE]

---

JAN-27-07: By now most are familiar with the recent fortunes of anti-bleeding drug Trasylol, and how it has been pulled from world markets after studies have revealed links to heart attack, stroke and kidney failure. A major Canadian study was halted back in October after concern over the death rate of aprotinin (Trasylol) participants. The US Food and Drug Administration (FDA) requested that Trasylol be withdrawn, and Trasylol maker Bayer AG complied pending thorough analysis of the Canadian BART study data. [MORE: TRASYLOL RISKS OUTWEIGH BENEFITS]

---

JAN-07-07: An October 4, 2006 editorial, titled, "Bayer's Duplicity on Drug Safety," in the New York Times said: "Bayer A.G.'s limp excuse for withholding data suggesting that a heart-surgery drug is dangerous won't wash." [MORE: TRASYLOL EXCUSE NOT GOOD ENOUGH]

---

OCT-30-07: In what amounts to a further damnation of Bayer AG's Trasylol and a huge setback for the manufacturer, the US Food and Drug Administration (FDA) announced in a joint communiqu� with Bayer AG that a Canadian clinical trial has been halted over concerns that one of the drugs being reviewed increases the risk of death. [MORE: TRASYLOL TRIALS HALTED]

---

AUG-05-07: A drug designed to inhibit bleeding during surgery is proving to have serious side effects. Trasylol, made by Bayer AG, can have an impact on the heart and kidney - leaving some patients on kidney dialysis, others with heart problems, and still others dead from the side effects association with Trasylol. [MORE: TRASYLOL EXPENSIVE AND DANGEROUS]

---

JUN-11-07: As more reports about the dangers of Trasylol are made public, Bayer A.G. defending itself and its drug more often. In the past year, two studies have shown that use of Trasylol can increase the risk of death in heart surgery patients. [MORE: BAYER DEFENDS TRASYLOL]

---

MAR-3-08: It has been revealed that the death and injury toll now likely exceeds 10,000 Floridians killed or crippled by side effects of Trasylol. [: SUN HERALD: TRASYLOL]

FEB-26-08: Two more studies have found that heart surgery patients were more likely to die if given the anti-bleeding drug Trasylol, renewing the claims that the drug is dangerous. [ TIMES LEADER: TRASYLOL]

FEB-17-08: In 2006, a study showed widespread death associated with Trasylol, and as it turns out there was concern long before that. [CBS NEWS: TRASYLOL]

FEB-15-08: According to a respected researcher, an estimated 22,000 lives could have been saved if the FDA had removed the drug Trasylol from the market two years ago. [RED ORBIT: TRASYLOL]

NOV-29-07: The UK's Commission on Human Medicines says that marketing authorization for Trasylol will be suspended until the results of a Europe-wide review of the drug are released. [CNN MONEY: TRASYLOL]

NOV-5-07: Bayer AG has halted sales of Trasylol after a request by the FDA. A Canadian clinical study found Trasylol could be linked to a higher risk of death than other drugs. [ASSOCIATED PRESS: TRASYLOL]

AUG-05-07: A number of lawsuits have been filed against Bayer, alleging the drug company hid the risks of Trasylol from physicians and patients. The company also failed to inform the FDA about a study that called into question Trasylol's safety. [TIMES: TRASYLOL]

FEB-13-07: Trasylol, used to prevent excessive bleeding during heart surgery, appears to raise the risk of dying in the five years afterward by nearly 50 percent. [SAUK VALLEY: TRASYLOL DEATH]

FEB-07-07: JAMA study reveals that Aprotinin treatment (Trasylol) resulted in 223 deaths among 1072 patients [20.8% 5-year mortality] and was associated with significantly increased mortality compared with control (128 deaths among 1009 patients [12.7%]. [JAMA: TRASYLOL RISK]

JAN-27-07: Bayer halts Trasylol clinical trials as new FDA label requirements must include a warning that Trasylol increases the possible risk for kidney damage. [NEWSINFERNO: TRASYLOL KIDNEY DAMAGE]